Despite compelling evidence supporting the efficacy of bispecific antibodies in relapsed/refractory cancers, clinical adoption is hindered by knowledge gaps in mitigating and managing toxicities.

This practical guide will help bridge some of these gaps by providing key insights into the complex landscape of ADCs, including their mechanisms of action, clinical applications, and limitations.

This monograph provides a comprehensive overview of biosimilars in oncology, addressing key barriers to adoption and offering practical guidance for their implementation in clinical practice.

MICROLEARNING In for the Long Haul: Identifying and Managing Residual MDD Symptoms – Module 2

Available until 6/3/2026
0.25 CME credits available
Posted by QDCME on 6/6/2025

Learn anytime, anywhere with our 15-minute interactive microlearning activity—quick, engaging, and designed to fit your busy schedule!

MICROLEARNING In for the Long Haul: Identifying and Managing Residual MDD Symptoms – Module 1

Available until 6/3/2026
0.25 CME credits available
Posted by QDCME on 6/6/2025

Learn anytime, anywhere with our 15-minute interactive microlearning activity—quick, engaging, and designed to fit your busy schedule!

Expert faculty will provide insights into the patient point of view on PDE4 inhibitors for the treatment of adult plaque psoriasis.

Expert faculty will provide insights into best practices and emerging evidence in the treatment of atopic dermatitis in children and adolescents.

In module 2 of this podcast, expert faculty will explore actionable insights and testing recommendations for HER2 alterations in NSCLC.

In this podcast, expert faculty will explore actionable insights and testing recommendations for HER2 alterations in NSCLC.

Collaborative Efforts in Early Detection and Intervention for Alzheimer’s Disease

Available until 1/14/2026
1.0 CME credit available
Posted by MLI Education on 6/4/2025

This program for family medicine & primary care clinicians who play a role in identifying and managing patients at risk of early Alzheimer’s disease (AD) and cognitive impairment.